“Long-Term Safety of Sonidegib in Basal Cell Carcinoma: 30-Month Results from the BOLT Trial”. SKIN The Journal of Cutaneous Medicine, vol. 2, no. S1, Feb. 2018, p. S47, https://doi.org/10.25251/skin.2.supp.47.